t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
Company profile
Ticker
TTOO
Exchange
Website
CEO
John Sperzel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
T2 Biosystems Securities Corporation ...
TTOO stock data
Latest filings (excl ownership)
S-1
IPO registration
22 Apr 24
8-K
Entry into a Material Definitive Agreement
18 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
12 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Regulation FD Disclosure
28 Mar 24
8-K
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
20 Mar 24
8-K
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
18 Mar 24
8-K
Other Events
12 Mar 24
DEF 14A
Definitive proxy
4 Mar 24
8-K
Results of Operations and Financial Condition
16 Feb 24
Transcripts
TTOO
Earnings call transcript
2023 Q4
15 Feb 24
TTOO
Earnings call transcript
2023 Q3
12 Oct 23
TTOO
Earnings call transcript
2023 Q2
7 Aug 23
TTOO
Earnings call transcript
2023 Q1
23 May 23
TTOO
Earnings call transcript
2022 Q4
13 Mar 23
TTOO
Earnings call transcript
2022 Q3
11 Nov 22
TTOO
Earnings call transcript
2022 Q2
16 Aug 22
TTOO
Earnings call transcript
2022 Q1
6 May 22
TTOO
Earnings call transcript
2021 Q4
18 Feb 22
TTOO
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
SC 13D
CR Group L.P.
19 Apr 24
4
Change in insider ownership
16 Apr 24
SC 13G
Safier Jacob
11 Mar 24
SC 13G
New Dimensions Trading
11 Mar 24
4
John J Sperzel III
27 Feb 24
4
John M Sprague
27 Feb 24
4
Michael Terrence Gibbs
27 Feb 24
4
Michael Terrence Gibbs
20 Feb 24
4
John M Sprague
20 Feb 24
4
John J Sperzel III
20 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 24.32 mm | 24.32 mm | 24.32 mm | 24.32 mm | 24.32 mm | 24.32 mm |
Cash burn (monthly) | (no burn) | (no burn) | 4.54 mm | 4.16 mm | 4.46 mm | 4.09 mm |
Cash used (since last report) | n/a | n/a | 31.20 mm | 28.58 mm | 30.71 mm | 28.11 mm |
Cash remaining | n/a | n/a | -6.88 mm | -4.26 mm | -6.39 mm | -3.79 mm |
Runway (months of cash) | n/a | n/a | -1.5 | -1.0 | -1.4 | -0.9 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 47 |
Opened positions | 22 |
Closed positions | 10 |
Increased positions | 13 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 7.62 bn |
Total shares | 100.77 mm |
Total puts | 277.00 k |
Total calls | 234.40 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
CR | 72.50 mm | $5.15 mm |
Vanguard | 5.88 mm | $1.30 bn |
Goldman Sachs & Co | 4.36 mm | $5.41 mm |
BLK Blackrock | 3.70 mm | $816.51 mm |
Aisling Capital Iii | 2.83 mm | $0.00 |
Gsa Capital Partners | 2.58 mm | $570.00 k |
Geode Capital Management | 2.41 mm | $531.57 mm |
Flagship Ventures Fund 2004 L P | 1.63 mm | $0.00 |
Lind Global Fund II | 1.02 mm | $815.00 k |
Jane Street | 646.89 k | $142.90 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Apr 24 | CR | Common Stock | Grant | Acquire A | Yes | No | 0 | 390,142 | 0.00 | 878,415 |
12 Apr 24 | CR | Common Stock | Grant | Acquire A | Yes | No | 0 | 1,647,315 | 0.00 | 1,983,262 |
12 Apr 24 | CR | Common Stock | Grant | Acquire A | Yes | No | 0 | 136,409 | 0.00 | 136,409 |
12 Apr 24 | CR | Common Stock | Grant | Acquire A | Yes | No | 0 | 424,716 | 0.00 | 424,716 |
12 Apr 24 | CR | Common Stock | Grant | Acquire A | Yes | No | 0 | 682,036 | 0.00 | 682,036 |
12 Apr 24 | CR | Series A Convertible Preferred Stock Common Stock | Grant | Acquire A | Yes | No | 0 | 17,160.48 | 0.00 | 28,035.73 |
24 Feb 24 | John J Sperzel III | Common Stock | Option exercise | Acquire M | No | No | 0 | 67 | 0.00 | 400 |
24 Feb 24 | John J Sperzel III | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 67 | 0.00 | 0 |
24 Feb 24 | John M Sprague | Common Stock | Option exercise | Acquire M | No | No | 0 | 29 | 0.00 | 141 |
24 Feb 24 | John M Sprague | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 29 | 0.00 | 0 |
News
T2 Biosystems Receives Notice Of Allowance For U.S. Patent Titled 'METHODS AND SYSTEMS FOR AMPLIFICATION IN COMPLEX SAMPLES (INCLUDING DIAGNOSTIC AND THERAPEUTICS METHODS FOR PATHOGENS IN WHOLE BLOOD)'
25 Apr 24
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
23 Apr 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
23 Apr 24
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
23 Apr 24
Why Riot Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
22 Apr 24
Press releases
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
11 Apr 24
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
20 Mar 24
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
18 Mar 24
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
15 Feb 24